ASPP2 suppresses squamous cell carcinoma via RelA/p65-mediated repression of p63

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 44, 2013, Pages 17969-17974

  Tordella, Luca ^a   Koch, Sofia ^a   Salter, Victoria ^a   Pagotto, Anna ^a   Doondeea, Jessica B ^b   Feller, Stephan M ^b   Ratnayaka, Indrika ^a   Zhong, Shan ^a   Goldin, Robert D ^c   Lozano, Guillermina ^d   McKeon, Frank D ^e   Tavassoli, Mahvash ^f   Fritzsche, Florian ^a,g   Huber, Gerhard F ^g   Rössle, Matthias ^g   Moch, Holger ^g   Lu, Xin ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARISOPRODOL; I KAPPA B; PROTEIN ASPP2; PROTEIN P63; SYNAPTOTAGMIN I; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; HETEROZYGOSITY; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; UPREGULATION;

INFLAMMATION; STRATIFIED EPITHELIAL CELL TUMOR; T53BP2;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE; CROSSES, GENETIC; DISEASE MODELS, ANIMAL; DNA PRIMERS; HAPLOINSUFFICIENCY; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MICE; MICE, INBRED BALB C; MICROARRAY ANALYSIS; PHOSPHOPROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTION FACTOR RELA; TUMOR SUPPRESSOR PROTEINS;

EID: 84887055453     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1309362110     Document Type: Article

References (39)

1. Quintanilla M, Brown K, Ramsden M, Balmain A (1986) Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 322(6074):78-80.
2. Vitale-Cross L, Amornphimoltham P, Fisher G, Molinolo AA, Gutkind JS (2004) Conditional expression of K-ras in an epithelial compartment that includes the stem cells is sufficient to promote squamous cell carcinogenesis. Cancer Res 64(24):8804-8807.
3. Kemp CJ, Donehower LA, Bradley A, Balmain A (1993) Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 74(5):813-822.
4. Martínez-Cruz AB, et al. (2008) Spontaneous squamous cell carcinoma induced by the somatic inactivation of retinoblastoma and Trp53 tumor suppressors. Cancer Res 68(3):683-692.
5. Qiao W, et al. (2006) Hair follicle defects and squamous cell carcinoma formation in Smad4 conditional knockout mouse skin. Oncogene 25(2):207-217.
6. Seitz CS, Lin Q, Deng H, Khavari PA (1998) Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proc Natl Acad Sci USA 95(5):2307-2312.
7. van Hogerlinden M, Rozell BL, Ahrlund-Richter L, Toftgard R (1999) Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kappaB signaling. Cancer Res 59(14):3299-3303.
8. Dajee M, et al. (2003) NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421(6923):639-643.
9. Liu B, et al. (2006) A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas. Proc Natl Acad Sci USA 103(46): 17202-17207.
10. Sen T, Chang X, Sidransky D, Chatterjee A (2010) Regulation of Np63 by NF. Cell Cycle 9(24):4841-4847.
11. Nguyen BC, et al. (2006) Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. Genes Dev 20(8):1028-1042.
12. Mills AA, et al. (1999) p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398(6729):708-713.
13. Yang A, et al. (1999) p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398(6729):714-718.
14. Di Como CJ, et al. (2002) p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 8(2):494-501.
15. Stiewe T (2007) The p53 family in differentiation and tumorigenesis. Nat Rev Cancer 7(3):165-168.
16. Su X, et al. (2009) TAp63 prevents premature aging by promoting adult stem cell maintenance. Cell Stem Cell 5(1):64-75.
17. Candi E, et al. (2007) TAp63 and DeltaNp63 in cancer and epidermal development. Cell Cycle 6(3):274-285.
18. Koster MI, Roop DR (2007) Mechanisms regulating epithelial stratification. Annu Rev Cell Dev Biol 23:93-113.
19. Keyes WM, et al. (2011) Np63 is an oncogene that targets chromatin remodeler Lsh to drive skin stem cell proliferation and tumorigenesis. Cell Stem Cell 8(2):164-176.
20. Sniezek JC, Matheny KE, Westfall MD, Pietenpol JA (2004) Dominant negative p63 isoform expression in head and neck squamous cell carcinoma. Laryngoscope 114(12): 2063-2072.
21. Samuels-Lev Y, et al. (2001) ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 8(4):781-794.
22. Bergamaschi D, et al. (2004) ASPP1 and ASPP2: Common activators of p53 family members. Mol Cell Biol 24(3):1341-1350.
23. Bergamaschi D, et al. (2003) iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet 33(2):162-167.
24. Vives V, et al. (2006) ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth. Genes Dev 20(10):1262-1267.
25. Kampa KM, et al. (2009) Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds. Proc Natl Acad Sci USA 106(11):4390-4395.
26. Wang XD, et al. (2011) SUMO-modified nuclear cyclin D1 bypasses Ras-induced senescence. Cell Death Differ 18(2):304-314.
27. Wang Y, et al. (2012) Autophagic activity dictates the cellular response to oncogenic RAS. Proc Natl Acad Sci USA 109(33):13325-13330.
28. Notari M, et al. (2011) Inhibitor of apoptosis-stimulating protein of p53 (iASPP) prevents senescence and is required for epithelial stratification. Proc Natl Acad Sci USA 108(40):16645-16650.
29. Chikh A, et al. (2011) iASPP/p63 autoregulatory feedback loop is required for the homeostasis of stratified epithelia. EMBO J 30(20):4261-4273.
30. Lu M, et al. (2013) Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. Cancer Cell 23(5):618-633.
31. Kuperwasser C, et al. (2000) Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. Am J Pathol 157(6): 2151-2159.
32. Sottocornola R, et al. (2010) ASPP2 binds Par-3 and controls the polarity and proliferation of neural progenitors during CNS development. Dev Cell 19(1):126-137.
33. Ziegler A, et al. (1994) Sunburn and p53 in the onset of skin cancer. Nature 372(6508): 773-776.
34. Ruptier C, et al. (2011) TP63 P2 promoter functional analysis identifies α-catenin as a key regulator of Np63 expression. Oncogene 30(46):4656-4665.
35. Lefort K, et al. (2007) Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases. Genes Dev 21(5):562-577.
36. Yang JP, et al. (1999) NF-kappaB subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2. Oncogene 18(37):5177-5186.
37. Wang Y, et al. (2013) ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells. Cell Death Differ 20(4):525-534.
38. Pal-Ghosh S, Tadvalkar G, Jurjus RA, Zieske JD, Stepp MA (2008) BALB/c and C57BL6 mouse strains vary in their ability to heal corneal epithelial debridement wounds. Exp Eye Res 87(5):478-486.
39. Sgroi DC, et al. (1999) In vivo gene expression profile analysis of human breast cancer progression. Cancer Res 59(22):5656-5661.